Laurus Labs (BOM:540222) Other Financing: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540222 Laurus Labs Ltd BOM:540222
66 GF Score
Price ₹1,602.30
GF Value ₹809.50
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Laurus Labs Other Financing?

Laurus Labs BOM:540222 +2.17% 66 Other Financing is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹809.50 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Laurus Labs's Other Financing for the three months ended in Jun. 2026 was ₹0 Mil.

Laurus Labs's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Laurus Labs Other Financing Historical Data

* Premium members only.

The historical data trend for Laurus Labs's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laurus Labs Other Financing Chart

Laurus Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -850.00 -1,404.00 -1,743.10 -682.30 -1,283.10

Laurus Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:540222
66GF Score
Laurus Labs Ltd BOM:540222
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laurus Labs Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ₹0 Mil mean?
Laurus Labs (BOM:540222) has a Other Financing of ₹0 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Laurus Labs and its competitors.
Is Laurus Labs' Other Financing too high?
Laurus Labs' current Other Financing is ₹0 Mil. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Other Financing compare to ZTS?
Laurus Labs' Other Financing of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Laurus Labs and its competitors. Laurus Labs's current Other Financing is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹809.50, compared to a current price of ₹1,602.30 — trading 97.9% above its estimated fair value. The current Other Financing is ₹0 Mil. Laurus Labs' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Other Financing is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laurus Labs (BOM:540222) Overvalued in 2026?

Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued. The current stock price of ₹1,602.30 is trading 97.9% above its estimated GF Value™ of ₹809.50. GuruFocus considers Laurus Labs to be Significantly Overvalued.

Key valuation signals for BOM:540222:

  • Other Financing: ₹0 Mil
  • GF Value™: ₹809.50 vs. price of ₹1,602.30 (97.9% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laurus Labs Business Description

Other Exchanges LAURUSLABS:India
Address Road No.1, Jubilee Hills, Plot No.103, Hyderabad, TG, IND, 500033
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score

Get the complete analysis for BOM:540222

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,602.30
Price
₹809.50
GF Value